Page 131 - Read Online

Fang et al. Cancer Drug Resist. 2025;8:42 Page 11 of 13

Writing - original draft, methodology, software, visualization: Zhang Q
Writing - original draft, visualization: Fang R
Writing - review and editing, formal analysis: Li Y
Visualization: Bai J
Data curation: Huang X
Project administration, data curation: Lu J
Investigation, resources: Chen D
Conceptualization, writing - review and editing: Zhang Y
Writing – reviewing and editing, supervision: Chen Z
The work reported in the paper has been performed by the authors, unless clearly specified in the text.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding authors
upon reasonable request.

Financial support and sponsorship
None.

Conflicts of interest
Chen D, Zhang Q, and Zhang Y are employees of Jiangsu Simcere Diagnostics Co., Ltd. Other authors
declared that there are no conflicts of interest.

Ethical approval and consent to participate
This study was approved by the Medical Ethics Committee of Nanjing Simcere Medical Laboratory
(NSML-IRB-202401-MS08; January 12, 2024). Written informed consent was obtained from all patients.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

Supplementary Materials
Supplementary Materials

REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63. DOI PubMed
2. Petrelli F, Lorini L, Paderno A, et al. Treatment of primary tumor in metastatic head and neck carcinoma: a systematic review and
meta-analysis. Oral Oncol. 2025;163:107248. DOI PubMed
3. Szturz P, Fuereder T, Guo Y, et al. Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell
carcinoma of the head and neck. Cancer Treat Rev. 2025;135:102910. DOI PubMed
4. Liu X, Harbison RA, Varvares MA, Puram SV, Peng G. Immunotherapeutic strategies in head and neck cancer: challenges and
opportunities. J Clin Invest. 2025;135:e188128. DOI PubMed PMC
5. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med.
2016;375:1856-67. DOI PubMed PMC
6. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous
cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-65. DOI
PubMed
7. Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab
with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised,
open-label, phase 3 study. Lancet. 2019;394:1915-28. DOI PubMed

124